Filtered By:
Condition: Atrial Fibrillation
Countries: Turkey Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 89 results found since Jan 2013.
The effect of treatment strategy on long-term follow-up results in patients with nonvalvular atrial fibrillation in Turkey: AFTER-2 subgroup analysis
CONCLUSION: It was found that rhythm control strategy is preferred in AF patients in Turkey. We found a lower rate of ischemic CVD/TIA in patients in the rhythm control group. Although no difference was observed in mortality rates, we found a higher rate of hospitalization in the rhythm control group.PMID:37329474 | DOI:10.1007/s40520-023-02467-y
Source: Aging Clinical and Experimental Research - June 17, 2023 Category: Geriatrics Authors: Raif K ılıç Tuncay G üzel Adem Aktan Muhammed Demir Bayram Arslan Faruk Erta ş Source Type: research
PCR239 Physician and Patient Preferences for Oral Anticoagulation Therapy Decision-Making in Atrial Fibrillation: Results From a National Best-Worst Scaling Survey in Turkey (PREF-AF)
The objective of this study was to quantify the relative importance that patients and physicians in Turkey place on different OAC attributes when making treatment decisions in AF.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: K Kilickesmez, D Aras, M Degertekin, N Ozer, B Hacibedel, K Helvacioglu, U Koc, A Olmez, O Ergene Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
